2 results
Approved WMOWill not start
The objective of this study is to increase our understanding of the relationship between various parameters of functional lesion severity, to optimize adenosine-free evaluation of functional lesion severity.
Approved WMORecruiting
The objectives of this are to establish the safety, tolerability, and efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in HV and TED patients over a dose range of 3.0 to 20.0 mg/kg.